Compare Baxter International Inc (BAX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Baxter International Inc trades at $26.94 (market cap $14.27B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. The key difference: Baxter International Inc pays a 0.14% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Baxter International Inc nearer its low. Which is the better fit depends on your goals.
| BAX | QQQE | |
|---|---|---|
Market Cap | $14.27B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.35 | $122.72 |
52-Week Low | $15.80 | $96.06 |
Enterprise Value | $21.79B | — |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
QQQE trades at $123.25, up 0.9% on the day, with a bullish technical signal from moving averages but a neutral oscillator reading. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk in top holdings like tech giants. Recent news highlights its appeal as a defensive play amid the Nasdaq rally, with SpaceX's imminent inclusion potentially driving inflows.
The outlook remains positive given structural diversification benefits and growth exposure, though overbought RSI levels near 79 suggest near-term caution. Risks include market volatility and tech sector sensitivity, but analyst sentiment favors QQQE over market-cap-weighted peers for balanced Nasdaq participation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
